Keywords: Regeneron, Sanofi, SAR236553, REGN727, Ph II, Cholesterol lowerer

Positive results for Regeneron and Sanofi's SAR236553/REGN727

Article | 27 May 2012

Print This

USA-based Regeneron (Nasdaq: REGN) and French drug major Sanofi (Euronext: SAN) presented results of their third and final Phase II ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in